Home / News / India News / Article /
Govt caps trade margins on non-scheduled cancer drugs at 30 pc of MRP; patients may save Rs 2,500 cr
Updated On: 09 October, 2026 11:01 AM IST | New Delhi | mid-day online correspondent
Under the new measure, margins charged on the supply and sale of non-scheduled anti-cancer drugs will be limited to 30 per cent of their maximum retail price (MRP). These medicines fall outside the list of drugs covered by government-fixed ceiling prices

Representational Image
The government has approved a cap on trade margins for non-scheduled anti-cancer medicines, aiming to curb excessive mark-ups and reduce treatment costs for patients. The move is expected to lower prices of affected medicines by up to 70 per cent and generate annual savings of around Rs 2,500 crore, according to the Department of Pharmaceuticals.
Trade margins capped at 30 per cent of MRP
Under the new measure, margins charged on the supply and sale of non-scheduled anti-cancer drugs will be limited to 30 per cent of their maximum retail price (MRP). These medicines fall outside the list of drugs covered by government-fixed ceiling prices.


